Sponsor or institution

Clinical trials and research at Ascentage Pharma Group Inc.

• 22Clinical trials
• 27Countries

Newest trials

All recruiting trials (22)

• APG-3288 in relapsed/refractory blood cancers

  This study tests APG-3288 alone to see if it can be safely given and what dose works best in people whose blood cancers have returned or stopped responding to standard treatments.

  Recruiting at 5 sites Phase 1 Ascentage Pharma Group Inc. · Los Angeles, California and 5 other locations · NCT07424833

• How olverembatinib is processed in people with liver impairment

  This test gives a single 20 mg dose of olverembatinib to people with different levels of chronic liver impairment and matched healthy volunteers to see how the drug is absorbed, distributed, metabolized, and cleared.

  Recruiting Phase 1 Ascentage Pharma Group Inc. · Suzhou, Jiangsu · NCT07282093

• Evaluating APG-2449 for treating advanced ovarian cancer and solid tumors

  This study is testing a new drug called APG-2449 to see if it can safely help people with advanced ovarian cancer and other solid tumors, both on its own and when combined with another treatment.

  Recruiting Phase 1 Ascentage Pharma Group Inc. · Guangzhou, Guangdong · NCT06687070

• Combining Lisaftoclax with Azacitidine for treating higher-risk Myelodysplastic Syndrome

  This study is testing if combining Lisaftoclax with azacitidine can help people newly diagnosed with higher-risk Myelodysplastic Syndrome live longer compared to just using azacitidine with a placebo.

  Recruiting at 143 sites Phase 3 Ascentage Pharma Group Inc. · Birmingham, Alabama and 154 other locations · NCT06641414

• Olverembatinib for treating SDH-deficient GIST

  This study is testing if a new medication called olverembatinib can help people with a specific type of gastrointestinal tumor feel better after they’ve already tried one other treatment.

  Recruiting Phase 3 Ascentage Pharma Group Inc. · Guangzhou, Guangdong · NCT06640361

• Treatment of Chronic Myeloid Leukemia with Olverembatinib

  This study is testing if a new drug called olverembatinib can help people with chronic myeloid leukemia feel better compared to an existing treatment, and it looks at two groups of patients based on a specific genetic mutation.

  Recruiting at 135 sites Phase 3 Ascentage Pharma Group Inc. · Birmingham, Alabama and 162 other locations · NCT06423911

• Combining APG-2575 with Azacitidine for treating Acute Myeloid Leukemia

  This study is testing if a new treatment combining APG-2575 with azacitidine can help people with newly diagnosed acute myeloid leukemia who can't have standard chemotherapy feel better compared to a placebo with azacitidine.

  Recruiting at 6 sites Phase 3 Ascentage Pharma Group Inc. · Tianjin, Tianjin Municipality and 5 other locations · NCT06389292

• Combining Lisaftoclax and Acalabrutinib for Newly Diagnosed CLL/SLL

  This study is testing if a new combination of two drugs, Lisaftoclax and Acalabrutinib, can work better than standard treatment for people who have just been diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting at 4 sites Phase 3 Ascentage Pharma Group Inc. · Bengbu, Anhui and 9 other locations · NCT06319456

• Evaluating APG-2575 for mild-to-moderate lupus

  This study is testing a new drug called APG-2575 to see if it is safe and effective for people with mild-to-moderate lupus.

  Recruiting Phase 1/2 Ascentage Pharma Group Inc. · Shanghai, Shanghai Municipality · NCT06182969

• Investigating a new treatment for patients with CLL/SLL

  This study is testing if a new treatment combining lisaftoclax with BTK inhibitors can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already been treated with BTK inhibitors.

  Recruiting at 120 sites Phase 3 Ascentage Pharma Group Inc. · Tuscon, Arizona and 134 other locations · NCT06104566

• Evaluating Olverembatinib for Newly Diagnosed Ph+ ALL

  This study is testing if a new drug called Olverembatinib, used with chemotherapy, can help people with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia do better than the standard treatment with Imatinib and chemotherapy.

  Recruiting at 8 sites Phase 3 Ascentage Pharma Group Inc. · Birmingham, Alabama and 89 other locations · NCT06051409

• Investigating APG-5918 for Anemia Treatment

  This study is testing a new drug called APG-5918 to see if it can safely and effectively treat anemia in patients who have it, while also checking how it works in healthy people.

  Recruiting at 2 sites Phase 1 Ascentage Pharma Group Inc. · Guangzhou, Guangdong and 1 other locations · NCT05773586

• Treatment of recurrent or refractory neuroblastoma in children with APG-115 and APG-2575

  This study is testing a new treatment using two drugs, APG-115 and APG-2575, to see if they can help children with hard-to-treat neuroblastoma or solid tumors feel better.

  Recruiting at 3 sites Phase 1/2 Ascentage Pharma Group Inc. · Guangzhou, Guangdong and 2 other locations · NCT05701306

• APG-2575 treatment for patients with relapsed or refractory CLL/SLL

  This study is testing a new oral medication called APG-2575 to see if it can help people with relapsed or hard-to-treat Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).

  Recruiting at 4 sites Phase 2 Ascentage Pharma Group Inc. · Guangzhou, Guangdong and 10 other locations · NCT05147467

• Combining APG-115 with PD-1 inhibitor for advanced liposarcoma and solid tumors

  This study is testing if combining a new drug called APG-115 with a PD-1 inhibitor can safely help people with advanced liposarcoma and other solid tumors.

  Recruiting at 2 sites Phase 1/2 Ascentage Pharma Group Inc. · Guangzhou, Guangdong and 2 other locations · NCT04785196

• Treatment for patients with relapsed or refractory acute myeloid leukemia

  This study is testing a new treatment called APG-2575, both alone and with other drugs, to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia.

  Recruiting at 10 sites Phase 1/2 Ascentage Pharma Group Inc. · Beijing, Beijing Municipality and 11 other locations · NCT04501120

• Evaluating APG-115 and APG-2575 for T-Prolymphocytic Leukemia and Non-Hodgkin's Lymphoma

  This study is testing a new treatment using two drugs, APG-115 and APG-2575, to see if they can help people with relapsed or hard-to-treat T-Prolymphocytic Leukemia and Non-Hodgkin's Lymphoma feel better and improve their health.

  Recruiting Phase 2 Ascentage Pharma Group Inc. · Houston, Texas · NCT04496349

• APG-2575 treatment for relapsed/refractory CLL/SLL

  This study is testing a new treatment called APG-2575, both alone and with other medications, to see how well it works for people with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

  Recruiting at 17 sites Phase 1/2 Ascentage Pharma Group Inc. · Beijing, Beijing Municipality and 17 other locations · NCT04494503

• Evaluating HQP1351 for patients with resistant leukemia

  This study is testing a new drug called HQP1351 to see if it can help patients with resistant chronic myeloid leukemia or Philadelphia positive acute lymphoblastic leukemia feel better and respond to treatment.

  Recruiting at 9 sites Phase 1 Ascentage Pharma Group Inc. · Birmingham, Alabama and 8 other locations · NCT04260022

• Testing APG-2575 for treating chronic lymphocytic leukemia and small lymphocytic leukemia

  This study is testing a new drug called APG-2575 to see if it can safely help people with chronic lymphocytic leukemia or small lymphocytic leukemia, both on its own and when combined with other treatments.

  Recruiting at 9 sites Phase 1 Ascentage Pharma Group Inc. · Duarte, California and 8 other locations · NCT04215809

• APG-2449 for advanced solid tumors

  This study is testing a new oral medication called APG-2449 to see how well it works and what the safe dosage is for people with advanced solid tumors like non-small cell lung cancer.

  Recruiting at 7 sites Phase 1 Ascentage Pharma Group Inc. · Beijing, Beijing Municipality and 8 other locations · NCT03917043

• Testing HQP1351 for GIST and other solid tumors

  This study is testing a new drug called HQP1351 to see if it can help people with gastrointestinal stromal tumors and other solid tumors feel better and how much of the drug is safe to use.

  Recruiting at 6 sites Phase 1 Ascentage Pharma Group Inc. · Guangzhou, Guangdong and 5 other locations · NCT03594422

Quick answers

How many clinical trials run by Ascentage Pharma Group Inc. are recruiting right now?

22, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 27 countries. The most sites are in China (18 trials), United States (8 trials), Australia (5 trials), Canada (4 trials), France (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 8, Phase 3: 7, Phase 1/2: 5, Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →